Please sign in to follow a disease.
Frontotemporal dementia
MONDO:0017276Frontotemporal dementia (FTD) comprises a group of neurodegenerative disorders, characterized by progressive changes in behavior, executive dysfunction and language impairment, as a result of degeneration of the medial prefrontal and frontoinsular cortices. Four clinical subtypes have been identified: semantic dementia, progressive non-fluent aphasia, behavioral variant FTD and right temporal lobar atrophy.
Also known as: FTD, MSTD, frontotemporal lobe dementia (FLDEM)
178 clinical trials for this condition and its sub-types, 132 tagged with Frontotemporal dementia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Frontotemporal dementia
-
GRN-related frontotemporal lobar degeneration with Tdp43 inclusions 6 trials · 47 incl. sub-types
1 sub-type
- Progressive non-fluent aphasia 24 trials · 44 incl. sub-types Sub-types →
-
Behavioral variant of frontotemporal dementia 22 trials · 42 incl. sub-types
3 sub-types
-
Pick disease 35 trials
-
Inclusion body myopathy with Paget disease of bone and frontotemporal dementia 1 trial · 3 incl. sub-types
4 sub-types
- Inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1 2 trials
- Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 1 trial
- Inclusion body myopathy and brain white matter abnormalities 0 trials
- Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3 0 trials
Most studied deeper sub-types
-
Nasal spray of stem cell 'Messages' could slow rare brain disease
Disease control Not yet recruitingThis study tests a new nasal spray treatment for frontotemporal dementia (FTD), a brain disease that changes personality and language. The spray contains tiny particles from umbilical cord stem cells that may protect brain cells and reduce harmful protein buildup. About 33 adults…
Phase 1/2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Experimental antibody aims to repair brain connections in rare dementia
Disease control Not yet recruitingThis study tests a new drug called NS101 in 15 people with semantic variant primary progressive aphasia (svPPA), a rare type of frontotemporal dementia that affects language and memory. The drug is an antibody designed to help repair connections between brain cells. The main goal…
Phase 2 • Sponsor: Hee-Jin Kim • Aim: Disease control
Last updated Jun 26, 2026 14:05 UTC
-
AI listens for dementia: new speech test could speed up diagnosis
Diagnosis Not yet recruitingThis observational study will enroll 440 Danish-speaking adults over 50 to see if an artificial intelligence model can detect dementia and mild cognitive impairment from speech recordings. Participants will complete standard cognitive tests and describe a picture while being reco…
Sponsor: Zealand University Hospital • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New spinal fluid test aims to solve dementia misdiagnosis puzzle
Diagnosis Not yet recruitingThis study will test whether measuring a specific abnormal protein (alpha-synuclein) in spinal fluid can reliably distinguish dementia with Lewy bodies (DLB) from Alzheimer's disease. Researchers will collect samples and perform cognitive tests on 286 older adults with suspected …
Sponsor: University Hospital, Strasbourg, France • Aim: Diagnosis
Last updated Jun 26, 2026 16:49 UTC
-
Can sound waves soothe Dementia's emotional turmoil?
Symptom relief Not yet recruitingThis early study tests whether a single session of focused ultrasound—using sound waves to gently stimulate a specific brain region—can safely reduce emotional symptoms like agitation, irritability, and anxiety in people with mild dementia. Fifteen participants aged 45 to 80 with…
Sponsor: West Virginia University • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
Smart sensors could revolutionize dementia monitoring at home
Knowledge-focused Not yet recruitingThis study will test if wearable sensors can effectively monitor symptoms and daily function in people with frontotemporal dementia (FTD). Sixty adults with FTD will wear pendant and wrist sensors for two weeks at a time, every six months over two years. The goal is to develop di…
Sponsor: BioSensics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Smart sensors could revolutionize how we track FTD symptoms
Knowledge-focused Not yet recruitingThis study tests whether wearable sensors and computerized voice and thinking tests can reliably track symptoms in people with frontotemporal dementia (FTD). Twenty participants will wear sensors and complete assessments at home over 12 months. The goal is to develop digital biom…
Sponsor: BioSensics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC